BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Sputnik V vaccine demonstrates 92% efficacy

11 November 2020 | News

The worldâ??s first registered vaccine against coronavirus created on the well-studied platform of human adenoviral vectors demonstrated high efficacy



The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), has announced that the Sputnik V vaccine, the world's first registered vaccine against coronavirus (registered on the 11th of August under the emergency use authorization mechanism) created on the well-studied platform of human adenoviral vectors, demonstrated high efficacy. The confirmation is based on the first interim data from the largest double-blind, randomized, placebo-controlled Phase III clinical trials in Russia involving 40,000 volunteers.

The trials evaluated efficacy among over 16,000 volunteers who received the vaccine or placebo 21 days after the first injection. As a result of a statistical analysis of 20 confirmed cases of coronavirus, the case split between vaccinated individuals and those who received the placebo indicates that the Sputnik V vaccine had an efficacy rate of 92% after the second dose.

Separately, in September the vaccine was first administered to a group of volunteers from the "red zones" of Russian hospitals. The observation of additional 10,000 vaccinated volunteers representing medics and other high-risk groups under the civil use of the vaccine out of clinical trials also confirmed the vaccine's efficacy rate of over 90 percent.

The data received will be published by Gamaleya Center researchers in one of the world's leading peer-reviewed medical academic journals following an independent valuation of the data by leading epidemiology experts.

As of November 11, as part of the clinical trials in Russia's 29 medical centers, more than 20,000 volunteers were vaccinated with the first dose and over 16,000 volunteers with the first and the second dose of the vaccine. In addition, as of November 11, no unexpected adverse events were identified as part of the research.

Currently, Sputnik V Phase III clinical trials are approved and are undergoing in Belarus, the UAE, Venezuela and other countries, as well as Phase II-III in India.